CareLit · DOI-Nachweis · Senologie - Zeitschrift für Mammadiagnostik und -therapie
EMBER-4: a Phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy in patients with ER+, HER2− early breast cancer with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
DOI 10.1055/s-0043-1769141
Bibliografische Angaben
Nachweis in CareLit
Autor:innenN. Harbeck, K. Jhaveri, J. O'Shaughnessy, F. Andre, M. P. Goetz, M. Martin, F.-C. Bidard, Z. M. Thomas, S. R. Young, R. Ismail-Khan, L. M. Smyth, M. Gnant
ZeitschriftSenologie - Zeitschrift für Mammadiagnostik und -therapie
Ausgabe02/2023
Jahrgang / SeitenJg. 20 · S. e6-e7
Kernaussage aus der Literatur
Abstract-Vorschau
EMBER-4: a Phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy in patients with ER+, HER2− early breast cancer with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
Zitieren
Zitierempfehlung
N. Harbeck, K. Jhaveri, J. O'Shaughnessy, F. Andre, M. P. Goetz, M. Martin, F.-C. Bidard, Z. M. Thomas, S. R. Young, R. Ismail-Khan, L. M. Smyth, M. Gnant (2023) EMBER-4: a Phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy in patients with ER+, HER2− early breast cancer with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET. Senologie - Zeitschrift für Mammadiagnostik und -therapie, 20 (02), e6-e7. https://doi.org/10.1055/s-0043-1769141
Mit CareLit weiterarbeiten